From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Aficamten (CK-274) is a potent cardiacmyosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca 2+ release .
Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiacmyosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiacmyosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiacmyosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .
Mavacamten (Standard) is the analytical standard of Mavacamten. This product is intended for research and analytical applications. Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats .
Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats .
JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM .
Mavacamten-d1 (MYK461-d1; SAR439152-d1) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
Mavacamten-d5 (MYK461-d5; SAR439152-d5) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
Mavacamten-d6 (MYK461-d6; SAR439152-d6) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
Sevasemten is an orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten exhibits selectively myosin inhibition with IC50s of ≤10 μM (skeletal), >100 μM (cardiac), respectively. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models .
ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury .
Fluorescein-5-maleimide (N-(5-Fluoresceinyl)maleimide) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiacmyosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm .
Fluorescein-5-maleimide (N-(5-Fluoresceinyl)maleimide) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiacmyosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm .
Myhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiacmyosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) can be used to study the autoimmune pathways of myocarditis and dilated cardiomyopathy .
S2-16 is a synthetic peptide from the S2 region of cardiacmyosin. S2-16 is a cryptic epitope that induces myocarditis in Lewis rats. A cryptic epitope is an epitope that is not recognized by antibodies or T cells after the animal is immunized with the intact antigen. S2-16 can be used to study the mechanism of autoimmune myocarditis .
C protein Cardiac muscle isoform; C-protein; Cardiac muscle isoform; Cardiac MyBP C; Cardiac MyBP-C; Cardiacmyosin binding protein C ; Cardiac-type; CMH4; FHC; MYBP C; MYBPC; MYBPC3; myosin binding protein C Cardiac; myosin binding protein C Cardiac-type; myosin-binding protein C; myosin-binding protein C Cardiac type; MYPC3_HUMAN
MYBPC3 Protein, positioned in the crossbridge region of vertebrate striated muscle A bands, binds to myosin heavy chain (MHC), F-actin, and native thin filaments, influencing actin-activated myosin ATPase. Its presence suggests potential modulation of muscle contraction, indicating a functional impact on the contractile apparatus, or a structural role in muscle fibers. MYBPC3 Protein, Human (His-SUMO) is the recombinant human-derived MYBPC3 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
C protein Cardiac muscle isoform; C-protein; Cardiac muscle isoform; Cardiac MyBP C; Cardiac MyBP-C; Cardiacmyosin binding protein C ; Cardiac-type; CMH4; FHC; MYBP C; MYBPC; MYBPC3; myosin binding protein C Cardiac; myosin binding protein C Cardiac-type; myosin-binding protein C; myosin-binding protein C Cardiac type; MYPC3_HUMAN
MYBPC3 Protein, positioned in the crossbridge region of vertebrate striated muscle A bands, binds to myosin heavy chain (MHC), F-actin, and native thin filaments, influencing actin-activated myosin ATPase. Its presence suggests potential modulation of muscle contraction, indicating a functional impact on the contractile apparatus, or a structural role in muscle fibers. MYBPC3 Protein, Human (HEK293, His) is the recombinant human-derived MYBPC3 protein, expressed by HEK293 , with C-6*His labeled tag.
Mavacamten-d5 (MYK461-d5; SAR439152-d5) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
Mavacamten-d1 (MYK461-d1; SAR439152-d1) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
Mavacamten-d6 (MYK461-d6; SAR439152-d6) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiacmyosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
MYH6; MYH7; MYHC; MYHCA; MYHCB; myosin heavy chain 6; myosin heavy chain; myosin-6; myosin heavy chain; Cardiac muscle alpha isoform
WB, IHC-P
Human, Mouse, Rat
MYH6 Antibody (YA3200) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3200), targeting MYH6, with a predicted molecular weight of 224 kDa. MYH6 Antibody (YA3200) can be used for WB, IHC-P experiment in human, mouse, rat background.
MYL2 Antibody (YA2709) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2709), targeting MYL2, with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). MYL2 Antibody (YA2709) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
